Central Pharmaceuticals Ltd. (DSE: CENTRALPHL)
Bangladesh
· Delayed Price · Currency is BDT 14.10
+0.70 (5.22%)
At close: Feb 3, 2025
Central Pharmaceuticals Income Statement
Financials in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | 2019 - 2015 |
| Revenue | 7.02 | 29.6 | 29.33 | 26 | 148.15 | 140.09 | Upgrade
|
| Revenue Growth (YoY) | -87.04% | 0.93% | 12.81% | -82.45% | 5.75% | -54.44% | Upgrade
|
| Cost of Revenue | 28.46 | 50.21 | 58.36 | 63.58 | 118.89 | 629.42 | Upgrade
|
| Gross Profit | -21.44 | -20.61 | -29.03 | -37.58 | 29.27 | -489.33 | Upgrade
|
| Selling, General & Admin | 16.57 | 16.65 | 18.83 | 15.77 | 22.45 | 610.55 | Upgrade
|
| Other Operating Expenses | 0.44 | 0.44 | - | - | - | - | Upgrade
|
| Operating Expenses | 17.01 | 17.09 | 18.83 | 15.77 | 22.45 | 610.55 | Upgrade
|
| Operating Income | -38.45 | -37.7 | -47.86 | -53.35 | 6.82 | -1,100 | Upgrade
|
| Interest Expense | - | - | - | -17.36 | -21.36 | -9.95 | Upgrade
|
| Interest & Investment Income | 6.05 | 0.01 | 0 | 0 | 0.01 | 0.01 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.01 | -0.01 | -0.01 | -0.11 | -0.09 | -0.03 | Upgrade
|
| EBT Excluding Unusual Items | -32.41 | -37.71 | -47.87 | -70.82 | -14.63 | -1,110 | Upgrade
|
| Asset Writedown | -10.59 | -10.59 | - | - | - | - | Upgrade
|
| Pretax Income | -43 | -48.3 | -47.87 | -70.82 | -14.63 | -1,110 | Upgrade
|
| Income Tax Expense | -6.64 | -5.88 | -3.91 | -2.57 | -6.16 | -2.85 | Upgrade
|
| Net Income | -36.36 | -42.42 | -43.96 | -68.25 | -8.47 | -1,107 | Upgrade
|
| Net Income to Common | -36.36 | -42.42 | -43.96 | -68.25 | -8.47 | -1,107 | Upgrade
|
| Shares Outstanding (Basic) | 120 | 120 | 120 | 120 | 120 | 120 | Upgrade
|
| Shares Outstanding (Diluted) | 120 | 120 | 120 | 120 | 120 | 120 | Upgrade
|
| Shares Change (YoY) | -1.29% | - | - | - | - | - | Upgrade
|
| EPS (Basic) | -0.30 | -0.35 | -0.37 | -0.57 | -0.07 | -9.24 | Upgrade
|
| EPS (Diluted) | -0.30 | -0.35 | -0.37 | -0.57 | -0.07 | -9.24 | Upgrade
|
| Free Cash Flow | 2.46 | 2.97 | -0.33 | -1.12 | -4.78 | -0.41 | Upgrade
|
| Free Cash Flow Per Share | 0.02 | 0.02 | -0.00 | -0.01 | -0.04 | -0.00 | Upgrade
|
| Gross Margin | - | -69.62% | -98.99% | -144.57% | 19.75% | - | Upgrade
|
| Operating Margin | -547.78% | -127.37% | -163.18% | -205.21% | 4.60% | -785.11% | Upgrade
|
| Profit Margin | -518.02% | -143.31% | -149.88% | -262.51% | -5.72% | -790.20% | Upgrade
|
| Free Cash Flow Margin | 35.00% | 10.02% | -1.11% | -4.31% | -3.22% | -0.29% | Upgrade
|
| EBITDA | -15.08 | -13.66 | -21.11 | -23.59 | 39.71 | -1,064 | Upgrade
|
| EBITDA Margin | -214.86% | -46.15% | -71.98% | -90.75% | 26.80% | - | Upgrade
|
| D&A For EBITDA | 23.37 | 24.04 | 26.75 | 29.76 | 32.89 | 36.28 | Upgrade
|
| EBIT | -38.45 | -37.7 | -47.86 | -53.35 | 6.82 | -1,100 | Upgrade
|
| EBIT Margin | - | -127.37% | -163.18% | -205.21% | 4.60% | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.